search
Back to results

Bubiket Study: Ultrasound Guided Fascia Iliaca Nerve Block With Bupivacaine and Adjuvant Ketamine vs. Bupivacaine Alone

Primary Purpose

Pain, Musculoskeletal

Status
Withdrawn
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
Bupivacaine
Ketamine
Sponsored by
Antonios Likourezos
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Pain, Musculoskeletal

Eligibility Criteria

18 Years - 120 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • 18 years and older
  • Presenting with isolated hip or femur fracture confirmed on x-ray.

Exclusion Criteria:

  • Polytrauma
  • Unstable vitals signs
  • Allergy to Bupivacaine or Ketamine
  • Inability to give consent
  • Altered mental status
  • Greater than 100kg
  • Known end stage renal disease or hepatic dysfunction
  • Received > 2 doses of Morphine in ER prior to regional nerve block
  • Patients with failed nerve block (30 minute onset)

Sites / Locations

  • Maimonides Medical Center

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Nerve Block with Bupivacaine an

Nerve Block with Bupivacaine al

Arm Description

Patients will receive an ultrasound guided regional nerve block with Bupivacaine (0.5% or 5 mg/ml) 2.5 mg/kg (max dose 175 kg) + Ketamine (50 mg/ml) 2 mg/kg. Each patient will be given a volume of 40 mL - this will be a mixture of Bupivacaine, Ketamine and 0.9% NS to make up the full 40 ml.

Patients will receive an ultrasound guided regional nerve block with Bupivacaine 0.5% only. Each patient will be given a volume of 40 ml - this will be a mixture of Bupivacaine and 0.9% NS to make up the full volume of 40 mL

Outcomes

Primary Outcome Measures

time to first rescue analgesia post-regional nerve blockade
The difference in time from administration of pain medication to rescue analgesia

Secondary Outcome Measures

Pain score at 30 minutes
The pain score at 30 minutes at an 11 point Likert Numeric Rating Scale (0 = no pain; 5=moderate pain, and 10 = very severe pain)

Full Information

First Posted
April 4, 2019
Last Updated
October 4, 2021
Sponsor
Antonios Likourezos
search

1. Study Identification

Unique Protocol Identification Number
NCT03909594
Brief Title
Bubiket Study: Ultrasound Guided Fascia Iliaca Nerve Block With Bupivacaine and Adjuvant Ketamine vs. Bupivacaine Alone
Official Title
Ultrasound Guided Fascia Iliaca Nerve Block With Bupivacaine and Adjuvant Ketamine vs. Bupivacaine Alone in Patients With Hip or Femur Fracture: a Double Blind Randomized Clinical Trial (BupiKet)
Study Type
Interventional

2. Study Status

Record Verification Date
October 2021
Overall Recruitment Status
Withdrawn
Why Stopped
The COVID Pandemic delayed start of study and currently the investigators are not interested in conducting the study.
Study Start Date
January 1, 2022 (Anticipated)
Primary Completion Date
December 31, 2023 (Anticipated)
Study Completion Date
December 31, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Antonios Likourezos

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The project is meant to evaluate the effect of a combination of medications (Bupivacaine + Ketamine) used in an ultra-sound guided nerve block for patients presenting to the Emergency Department (ED) with hip and/or femur fractures. The goal is to see whether the combination of these two medications will result in greater and longer-lasting pain relief, longer-lasting motor and sensory block and overall less need for opioid rescue analgesia.
Detailed Description
STUDY DESIGN Subjects: Patients aged 18 years and older with isolated hip or femur fracture confirmed on x-ray. DESIGN: A randomized double-blind prospective superiority trail. Each patient will receive Morphine for analgesia prior to regional nerve block. Patients < 65 years will receive Morphine 0.1 mg/kg every four hours as needed for 2 doses Patients > 65 years will receive Morphine 0.05 mg/kg every four hours as needed for 2 doses Treatment group: will receive an ultrasound guided regional nerve block with Bupivacaine (0.5% or 5 mg/ml) 2.5 mg/kg (max dose 175 kg) + Ketamine (50 mg/ml) 2 mg/kg. Each patient will be given a volume of 40 mL - this will be a mixture of Bupivacaine, Ketamine and 0.9% NS to make up the full 40 ml. Control group: will receive an ultrasound guided regional nerve block with Bupivacaine 0.5% only. Each patient will be given a volume of 40 ml - this will be a mixture of Bupivacaine and 0.9% NS to make up the full volume of 40 mL The patients will be followed with respect to accrual time, follow up time, and total time of the block as well as a need for rescue analgesia as follows: every 15 minutes for the first hour; every 30 minutes for the next hour; every 1 hour for next 4 hours; every 4 hours for next 18 hours with end point of 24 hours or up until they are taken to surgery, whichever comes first. Evaluation of the sensory blocks: will be performed every 5 minutes after administration of the local anesthetic. The sensory block will be quantified as: 0 = Anesthesia (no sensation), 1 = Analgesia (decreased [dull] sensation), and 2 = no block (normal sensation), by using the pinprick test and comparing with the contralateral limb. The time elapsed from the injection to the onset of analgesia in the central sensory region of femoral nerve block will be taken as time of onset of the sensory block. Rescue Analgesia: If pain is not relieved and the participant requires rescue analgesia a weight-based dose of Morphine will be given at 0.1 mg/kg. In addition, an antidote (lipid emulsion) that will be given to patients who need it when they develop severe side effects. DATA COLLECTION: Patient demographic, clinical and injury information, pain score, onset of motor and sensory block, rescue analgesia and side effects/adverse events will be collected by using a data collection form by trained research assistant and associates. DATA ANALYSIS: Statistical Analyses will include frequency distributions, t-test and chi-square for comparison between and within the groups and Cox Linear Regression Analysis. P<.05 will denote statistical significance. Statistical analyses will be conducted via SPSS version 24. Antonios Likourezos or equivalent will perform the statistical analyses. EXPECTED OUTCOMES: PRIMARY OUTCOME: time to first rescue analgesia post-regional nerve blockade in each group SECONDARY OUTCOMES: • Change in pain score as measured by Visual Analog Scale: Patient to be approached at the following intervals: every 15 minutes for the first hour; every 30 minutes for the next hour; every 1 hour for next 4 hours; every 4 hours for next 18 hours with end point of 24 hours or up until they are taken to surgery, whichever comes first.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pain, Musculoskeletal

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Masking Description
This is a randomized double blind study - - All the pharmacist and research manager
Allocation
Randomized
Enrollment
0 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Nerve Block with Bupivacaine an
Arm Type
Experimental
Arm Description
Patients will receive an ultrasound guided regional nerve block with Bupivacaine (0.5% or 5 mg/ml) 2.5 mg/kg (max dose 175 kg) + Ketamine (50 mg/ml) 2 mg/kg. Each patient will be given a volume of 40 mL - this will be a mixture of Bupivacaine, Ketamine and 0.9% NS to make up the full 40 ml.
Arm Title
Nerve Block with Bupivacaine al
Arm Type
Active Comparator
Arm Description
Patients will receive an ultrasound guided regional nerve block with Bupivacaine 0.5% only. Each patient will be given a volume of 40 ml - this will be a mixture of Bupivacaine and 0.9% NS to make up the full volume of 40 mL
Intervention Type
Drug
Intervention Name(s)
Bupivacaine
Intervention Description
Bupivacaine
Intervention Type
Drug
Intervention Name(s)
Ketamine
Intervention Description
Ketamine
Primary Outcome Measure Information:
Title
time to first rescue analgesia post-regional nerve blockade
Description
The difference in time from administration of pain medication to rescue analgesia
Time Frame
0-24 hours
Secondary Outcome Measure Information:
Title
Pain score at 30 minutes
Description
The pain score at 30 minutes at an 11 point Likert Numeric Rating Scale (0 = no pain; 5=moderate pain, and 10 = very severe pain)
Time Frame
30 minutes

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
120 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: 18 years and older Presenting with isolated hip or femur fracture confirmed on x-ray. Exclusion Criteria: Polytrauma Unstable vitals signs Allergy to Bupivacaine or Ketamine Inability to give consent Altered mental status Greater than 100kg Known end stage renal disease or hepatic dysfunction Received > 2 doses of Morphine in ER prior to regional nerve block Patients with failed nerve block (30 minute onset)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Sergey Motov, MD
Organizational Affiliation
Maimonides Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Maimonides Medical Center
City
Brooklyn
State/Province
New York
ZIP/Postal Code
11219
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Bubiket Study: Ultrasound Guided Fascia Iliaca Nerve Block With Bupivacaine and Adjuvant Ketamine vs. Bupivacaine Alone

We'll reach out to this number within 24 hrs